Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529260 | 0.82 | PPARG (0.61) | PPARG | |
| SCHEMBL4600911 | 0.79 | PPARG (0.64) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL4665181 | 0.78 | PPARG (0.55) | PPARGLMNASMN1; SMN2 | |
| SCHEMBL3202753 | 0.77 | PPARG (0.58) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL3204135 | 0.77 | PPARG (0.60) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL4602176 | 0.76 | PPARG (0.74) | PPARG | |
| SCHEMBL4665185 | 0.76 | PPARG (0.56) | PPARGLMNASMN1; SMN2 | |
| SCHEMBL3206547 | 0.75 | PPARG (0.62) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL3216914 | 0.75 | PPARG (0.57) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL4666566 | 0.75 | PPARG (0.55) | PPARGALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885ALDH1A1 212/4885LMNA 1909/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885ALDH1A1 118/4885LMNA 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.